NEW YORK (GenomeWeb) – Liquid biopsy firm Biocept said today that it has closed a previously announced public stock offering, raising net proceeds of approximately $13.3 million after deducting fees and offering expenses from a total sale of $14.8 million.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.